Document ID: chunk:federal_register_of_legislation:F2025C00124:clause:3_1:p63
Version: federal_register_of_legislation:F2025C00124
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 63/476)
Character Range: 1180540–1188338

Authority Code 9591
                                                                                                                                            Patient must have a severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring hospital admissions more frequently than 3 times per year; OR
                                                                                                                                            Patient must have significant bronchiectasis on chest high resolution computed tomography scan; OR
                                                                                                                                            Patient must have severe cystic fibrosis bronchiolitis with persistent wheeze non‑responsive to conventional medicines; OR
                                                                                                                                            Patient must have severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy.
                                                                                                                                            Patient must be less than 5 years of age.
                                                                                                                                            Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit.
                                                                                                                                            Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented. Treatment with this drug should cease if there is not agreement of benefit, as there is always the possibility of harm from unnecessary use. Further reassessments must be undertaken and documented at six‑monthly intervals.
                                                                       C9592                                                                Cystic fibrosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures ‑ Streamlined Authority Code 9592
                                                                                                                                            Continuing treatment
                                                                                                                                            Patient must have initiated treatment with dornase alfa at an age of less than 5 years; AND
                                                                                                                                            Patient must have undergone a comprehensive assessment which documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit.
                                                                                                                                            Patient must be 5 years of age or older.
                                                                                                                                            Further reassessments must be undertaken and documented at six‑monthly intervals. Treatment with this drug should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use.
                                                                       C9624                                                                Cystic fibrosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures ‑ Streamlined Authority Code 9624
                                                                                                                                            Patient must be 5 years of age or older.
                                                                                                                                            Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit.
                                                                                                                                            Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease.
                                                                                                                                            Initial therapy is limited to 3 months treatment with dornase alfa at a dose of 2.5 mg daily.
                                                                                                                                            To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment:
                                                                                                                                            (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND
                                                                                                                                            (2) the patient or the patient's family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient.
                                                                                                                                            Further reassessments must be